Rigel Pharmaceuticals (RIGL) News Today $19.69 -0.85 (-4.16%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Hillsdale Investment Management Inc. Has $2.86 Million Stock Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Hillsdale Investment Management Inc. increased its holdings in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 814.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 170,100 shares of the biotechnoloMarch 24 at 5:42 AM | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.80 Average PT from BrokeragesMarch 22 at 1:17 AM | americanbankingnews.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Hold" by BrokeragesRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) has been given a consensus recommendation of "Hold" by the five brokerages that are presently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. ThMarch 19, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Increases Stock Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 42.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 139,128 shares oMarch 19, 2025 | marketbeat.comCatalyst Funds Management Pty Ltd Purchases 21,000 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Catalyst Funds Management Pty Ltd boosted its position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 777.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,700 shares of the biotechnology company's stMarch 17, 2025 | marketbeat.comGlobeflex Capital L P Acquires 43,095 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Globeflex Capital L P lifted its position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 468.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 52,295 shares of the biotMarch 16, 2025 | marketbeat.comStatutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings AreMarch 15, 2025 | finance.yahoo.comRigel Pharmaceuticals appoints new board memberMarch 12, 2025 | uk.investing.comRigel Pharmaceuticals Appoints Dr. Frohlich to BoardMarch 10, 2025 | tipranks.comRigel Pharmaceuticals Full Year 2024 Earnings: EPS Beats ExpectationsMarch 10, 2025 | finance.yahoo.comRigel Appoints Mark W. Frohlich, M.D. to Board of DirectorsMarch 10, 2025 | finance.yahoo.comRigel Appoints Mark W. Frohlich, M.D.March 10, 2025 | prnewswire.comCM Management LLC Sells 47,500 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)CM Management LLC lessened its position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 16.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 242,500 shares of the biotechnology company's stock after selling 47,500March 9, 2025 | marketbeat.comFY2025 EPS Estimates for RIGL Boosted by Cantor FitzgeraldRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 5th. Cantor Fitzgerald analyst K. Kluska now anticipates tMarch 8, 2025 | marketbeat.comResearch Analysts Set Expectations for RIGL Q1 EarningsRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Stock analysts at B. Riley issued their Q1 2025 earnings estimates for shares of Rigel Pharmaceuticals in a research note issued on Tuesday, March 4th. B. Riley analyst K. Patel anticipates that the biotechnology company will earn $0.10 peMarch 8, 2025 | marketbeat.comAnalysts Set Expectations for RIGL Q1 EarningsRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for shares of Rigel Pharmaceuticals in a research note issued on Wednesday, March 5th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company wilMarch 8, 2025 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to "Buy"StockNews.com cut shares of Rigel Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday.March 8, 2025 | marketbeat.comCitigroup Increases Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target to $55.00Citigroup raised their price objective on Rigel Pharmaceuticals from $49.00 to $55.00 and gave the stock a "buy" rating in a report on Thursday.March 7, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMarch 7, 2025 | finance.yahoo.comB. Riley Expects Stronger Earnings for Rigel PharmaceuticalsRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Stock analysts at B. Riley upped their FY2026 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 4th. B. Riley analyst K. Patel now forecasts that tMarch 7, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for RIGL Q3 Earnings?Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Rigel Pharmaceuticals in a report issued on Wednesday, March 5th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology companyMarch 7, 2025 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Given New $24.00 Price Target at B. RileyB. Riley lifted their target price on Rigel Pharmaceuticals from $20.00 to $24.00 and gave the stock a "neutral" rating in a report on Wednesday.March 6, 2025 | marketbeat.comRigel Pharmaceuticals price target raised to $55 from $49 at CitiMarch 6, 2025 | markets.businessinsider.comRigel Pharmaceuticals (NASDAQ:RIGL) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $57.00 price objective on shares of Rigel Pharmaceuticals in a research report on Wednesday.March 6, 2025 | marketbeat.comRigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor AppealMarch 6, 2025 | tipranks.comRigel Pharmaceuticals Reports Record Sales and Strategic GrowthMarch 5, 2025 | tipranks.comRigel Pharmaceuticals (NASDAQ:RIGL) Posts Earnings Results, Beats Estimates By $0.50 EPSRigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) posted its quarterly earnings results on Tuesday. The biotechnology company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.50. Rigel Pharmaceuticals had a negative return on equity of 14.80% and a net margin of 2.46%.March 5, 2025 | marketbeat.comRigel Pharmaceuticals price target raised to $24 from $20 at B. RileyMarch 5, 2025 | markets.businessinsider.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comRigel Pharmaceuticals, Inc.: Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 5, 2025 | finanznachrichten.deRigel Pharmaceuticals Inc (RIGL) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...March 5, 2025 | gurufocus.comQ4 2024 Rigel Pharmaceuticals Inc Earnings Call TranscriptMarch 5, 2025 | gurufocus.comRigel Pharmaceuticals, Inc. (RIGL) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | seekingalpha.comRigel Pharmaceuticals reports Q4 EPS 80c, consensus 58cMarch 4, 2025 | markets.businessinsider.comRigel Pharmaceuticals sees FY25 revenue $200M-$210M, consensus $204.88MMarch 4, 2025 | markets.businessinsider.comRigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 4, 2025 | prnewswire.comRigel Pharmaceuticals Inc (RIGL) Q4 2024: Everything You Need To Know Ahead Of EarningsMarch 3, 2025 | gurufocus.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Growth in Short InterestRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) was the recipient of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 1,350,000 shares, an increase of 140.8% from the January 31st total of 560,700 shares. Approximately 7.9% of the shares of the stock are short sold. Based on an average daily volume of 254,100 shares, the short-interest ratio is presently 5.3 days.March 2, 2025 | marketbeat.comLos Angeles Capital Management LLC Purchases 11,499 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Los Angeles Capital Management LLC lifted its position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 15.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 86,001 shares of the biotechnology company's stock after purchasing an additional 1March 1, 2025 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Lowered to "Buy" Rating by StockNews.comStockNews.com downgraded Rigel Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday.February 28, 2025 | marketbeat.comRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business UpdateFebruary 25, 2025 | prnewswire.comRigel Pharmaceuticals (RIGL) Projected to Post Quarterly Earnings on TuesdayRigel Pharmaceuticals (NASDAQ:RIGL) will be releasing earnings before the market opens on Tuesday, March 4.February 25, 2025 | marketbeat.comWith 57% ownership of the shares, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is heavily dominated by institutional ownersFebruary 23, 2025 | uk.finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Hold" from AnalystsShares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have been assigned an average recommendation of "Hold" from the five research firms that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and two havFebruary 22, 2025 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Shares Pass Above Two Hundred Day Moving Average - What's Next?Rigel Pharmaceuticals (NASDAQ:RIGL) Share Price Crosses Above 200-Day Moving Average - Time to Sell?February 18, 2025 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Large Growth in Short InterestRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 560,700 shares, a growth of 22.7% from the January 15th total of 456,900 shares. Based on an average trading volume of 301,900 shares, the days-to-cover ratio is currently 1.9 days. Currently, 3.3% of the company's shares are sold short.February 16, 2025 | marketbeat.comARMISTICE CAPITAL, LLC Reduces Stake in Rigel Pharmaceuticals IncFebruary 15, 2025 | gurufocus.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) CFO Sells $42,593.12 in StockFebruary 7, 2025 | insidertrades.comRigel Pharmaceuticals CFO Dean Schorno sells $80,614 in stockFebruary 7, 2025 | msn.comRigel Pharmaceuticals CEO Raul Rodriguez sells shares worth $200,075February 6, 2025 | msn.com Remove Ads Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address RIGL Media Mentions By Week RIGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RIGL News Sentiment▼1.150.63▲Average Medical News Sentiment RIGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RIGL Articles This Week▼43▲RIGL Articles Average Week Remove Ads Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Celldex Therapeutics News Novavax News OPKO Health News Geron News Innoviva News Myriad Genetics News Emergent BioSolutions News Verastem News Vanda Pharmaceuticals News Codexis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RIGL) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RIGL Stock Free RIGL Stock Alerts